Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

By Johnson Neil   Shapiro Geoffrey I  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 11, 2010-11 ,pp. : 1199-1212

Informa Healthcare

Access to resources Recommend Favorite

Novel -lactam antibiotics and inhibitor combinations

By Bassetti Matteo   Righi Elda   Viscoli Claudio  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 285-296

Informa Healthcare

Access to resources Recommend Favorite

Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors

By Puhlmann Ulrike   Schäfer Dirk   Ziemann Christina  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 4, 2006-04 ,pp. : 403-430

Informa Healthcare

Access to resources Recommend Favorite

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

By Patel Sharmila   Player Mark R  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 12, 2008-12 ,pp. : 1865-1882

Informa Healthcare

Access to resources Recommend Favorite

Optimism over new chemotherapy combinations for ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite